These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 15790787)

  • 21. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
    Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein.
    Lekmine F; Sassano A; Uddin S; Smith J; Majchrzak B; Brachmann SM; Hay N; Fish EN; Platanias LC
    Exp Cell Res; 2004 Apr; 295(1):173-82. PubMed ID: 15051500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism.
    Hara K; Yonezawa K; Weng QP; Kozlowski MT; Belham C; Avruch J
    J Biol Chem; 1998 Jun; 273(23):14484-94. PubMed ID: 9603962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
    Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
    Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
    Sheng Z; Ma L; Sun JE; Zhu LJ; Green MR
    Blood; 2011 Sep; 118(10):2840-8. PubMed ID: 21715304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
    Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
    J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
    Gu JJ; Santiago L; Mitchell BS
    Blood; 2005 Apr; 105(8):3270-7. PubMed ID: 15604220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
    Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1.
    El-Chaâr D; Gagnon A; Sorisky A
    Int J Obes Relat Metab Disord; 2004 Feb; 28(2):191-8. PubMed ID: 14970836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si
    Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.
    Masiello D; Mohi MG; McKnight NC; Smith B; Neel BG; Balk SP; Bubley GJ
    Cancer Biol Ther; 2007 Feb; 6(2):195-201. PubMed ID: 17218776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD; Nien WL; Dauphinee SM; Too CK
    J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
    Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular cross-talk between MEK1/2 and mTOR signaling during recovery of 293 cells from hypertonic stress.
    Naegele S; Morley SJ
    J Biol Chem; 2004 Oct; 279(44):46023-34. PubMed ID: 15292274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL2-dependent phosphorylation of 40S ribosomal protein S6 is controlled by PI-3K/mTOR signalling in CTLL2 cells.
    Tuhácková Z; Sloncová E; Vojtechová M; Sovová V
    Int J Mol Med; 2004 Apr; 13(4):601-5. PubMed ID: 15010863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway.
    Thyrell L; Hjortsberg L; Arulampalam V; Panaretakis T; Uhles S; Dagnell M; Zhivotovsky B; Leibiger I; Grandér D; Pokrovskaja K
    J Biol Chem; 2004 Jun; 279(23):24152-62. PubMed ID: 15056668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.